IMM 1.61% 31.5¢ immutep limited

next 3 - 6 months

  1. 115 Posts.
    Next 3 - 12 months would make or break prr. Positive outcomes which would potential see the sp get close its 10-yr highs & maybe beyond:
    1) ODS approval from US FDA - significantly milestone
    2) Significant positive update on PIIb/III trials
    3) Approval or consideration for CVac approval in jurisdictions other than the US
    4) Major re-rating
    5) Partnership from big pharmas

    Pontential PRR breakers/set backs would be the opposite of above esp. (1) to (3). (1) & (2) would trigger largely be responsible for(4) & (5) to occur.

    The risks are currently still high but not as high as say 6 months ago. If, say, 1, (2) & (3) are achieved; risk would significantly be lower than current. This would be reflected in the sp.
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.